

Clinical trials of apixaban (without LMWH)

TrialResults-center www.trialresultscenter.org

1 venous thrombosis

Trial	Treatments	Patients	Trials design and methods
apixaban (without LMWH) vs LMWH/VKA			
AMPLIFY , 2013 [NCT00643201] n=2691/2704 follow-up: 6 mo	apixaban 10 mg twice daily for 7 days then 5 mg, twice daily, 6 months versus conventional therapy: enoxaparin 1mg/kg twice daily until INR \geq 2 then warfarin for an INR between 2-4, once daikly, 6 months	patients with deep vein thrombosis or pulmonary embolism	Parallel groups double blind
Botticelli DVT , 2008 [NCT00252005] n=358/118 follow-up:	apixaban 5 mg twice-daily, 10 mg twice-daily, or 20 mg once-daily for 84-91 days versus low molecular weight heparin followed by vitamin K antagonists	patients with symptomatic deep vein thrombosis	Parallel groups open

More details and results :

- antithrombotics for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q101>
- direct oral anticoagulant (DAO) for venous thrombosis in all types of patients at <http://www.trialresultscenter.org/go-Q505>

References

AMPLIFY, 2013:

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013 Aug 29;369:799-808 [23808982] [10.1056/NEJMoa1302507](https://doi.org/10.1056/NEJMoa1302507)

Botticelli DVT, 2008:

Buller H, Deitchman D, Prins M, Segers A Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008 Aug;6:1313-8 [18541000]

2 pulmonary embolism

Trial	Treatments	Patients	Trials design and methods
apixaban (without LMWH) vs LMWH/VKA			
AMPLIFY , 2013 [NCT00643201] n=2691/2704 follow-up: 6 mo	apixaban 10 mg twice daily for 7 days then 5 mg, twice daily, 6 months versus conventional therapy: enoxaparin 1mg/kg twice daily until INR.>=2 then warfarin for an INR between 2-4, once daikly, 6 months	patients with deep vein thrombosis or pulmonary embolism	Parallel groups double blind

More details and results :

- antithrombotics for pulmonary embolism in all type of patients at <http://www.trialresultscenter.org/go-Q102>

References

AMPLIFY, 2013:

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013 Aug 29;369:799-808 [23808982] 10.1056/NEJMoa1302507

Entry terms: apixaban, BMS 562247, BMS562247, BMS-562247, Eliquis,